Termination of License Rights. Customer’s license rights to the Software shall immediately cease upon termination of the license rights granted to the Customer under the Agreement.
Termination of License Rights. Upon termination of this Agreement for any reason with respect to all Licensed Gene Targets or with respect to all Licensed Products, the Agreement shall be terminated in its entirety and all license rights granted under Section 2.1 shall terminate immediately and automatically upon the effective date of such termination. Upon any termination of this Agreement in part on a Licensed Gene Target-by-Licensed Gene Target basis or a Licensed Product by Licensed Product basis under any of the provisions of this Article 10 (except for a termination under Section 10.2.2, for which the license termination consequences shall be as stated in Section 10.2.2), all license rights granted under Section 2.1 with respect to each such terminated Licensed Gene Target and each related Licensed Product for each such terminated Licensed Gene Target will terminate immediately and automatically upon the effective date of such termination.
Termination of License Rights. Unless and until the Non-Developing Party decides to Opt-in pursuant to the Opt In Trigger described herein, it shall have no further rights under the licenses provided to it under Article 11 with respect to such Independent Product or Independent Indication. *Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.
Termination of License Rights. The License Rights may be ----------------------------- terminated in the following circumstances, and upon the effective date of any such termination Genzyme's right to practice under the License Rights shall cease:
Termination of License Rights. Upon termination of this Agreement for any reason with respect to all Licensed Products, the Agreement shall be terminated in its entirety and all license rights granted under Section 2.1 shall terminate immediately and automatically upon the effective date of such termination.
Termination of License Rights. Upon any termination of Commercial Member’s membership in the Consortium for any reason, this Agreement and all rights granted to Commercial Member hereunder will immediately terminate. In the event that this Agreement is terminated, Commercial Member and its Resellers shall withdraw all inventories of the IntelliCAD Licensed Materials or any Member Application within ninety (90) days from the effective date of termination (the “Transition Period”). Any inventory remaining after the Transition Period must be destroyed at the Commercial Member’s sole cost. All IntelliCAD Base Software and ArchT Software source files must be destroyed immediately upon termination at the Commercial Member’s sole cost and Commercial Member shall certify such destruction to the Consortium within ten (10) days of the effective date of termination.
Termination of License Rights. Vyrex and IRC hereby agree that this Second Amendment terminates all rights of IRC under the sub-license covering CD-Tagging patent rights granted by Vyrex to IRC in the Agreement. IRC acknowledges and represents hereby that it has not, pursuant to the Agreement, granted any sub-license or conveyed any rights to any affiliate or third party with respect to CD-Tagging.
Termination of License Rights. If MRF terminates this Agreement with respect to any particular Consortium Inventions (or any patents and patent applications claiming the same) under Section 12.3(b), or if University terminates this Agreement in its entirety under Section 12.5, MRF license rights and related obligations (including, without limitation, payment obligations) under Section 5 with respect to the Consortium Inventions so affected shall immediately terminate. In such case, any sublicenses previously granted under Section 5.1(e)(ii) with respect to the affected Consortium Inventions shall survive, provided that University shall have the right to directly enforce such sublicenses as they apply to University Consortium Inventions sublicensed thereunder.
Termination of License Rights. After the Research Program Term, at such time as BMS provides timely notice to Tranzyme in a timely manner that it is no longer actively pursuing any Collaboration Lead as part of a BMS Discovery & Development Program for a Collaboration Target, all Collaboration Leads against such terminated Collaboration Target shall no longer be within the scope of this Agreement, including the licenses granted in Article 5. BMS shall use reasonable efforts to provide notice to Tranzyme of any such occurrence. PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS.
Termination of License Rights. In the event any Product supplied hereunder shall no longer be a Licensed Product under the License Agreement or Pfizer's license with respect thereto under the License Agreement is no longer in effect, then Pfizer's obligations to purchase and XOMA's obligation to supply such Product hereunder shall terminate.
